AI for Early Identification of Breast Cancer – Efficient and Accurate Diagnosis

By Michael Awood

September 15, 2023

Breast cancer is the second leading cause of cancer death in women. Early identification can ease this to ensure early access to treatment. Developed nations have vast mammography screening programs, but interpreting the images is still hard. The accuracy of cancer detection varies widely among experts, and the potential for improvement is significant. False positives can lead to patient anxiety, unnecessary follow-up, and invasive diagnostic procedures. Sometimes screening cannot identify cancers until they are more advanced and less amenable to treatment.

Artificial Intelligence (AI) can overcome this challenge. Studies show it can outperform human experts in many medical image analysis tasks. This leads us to evaluate AI’s potential to augment the early identification process of breast cancer through high-quality images.

Researchers recently tested a new AI system that predicts breast cancer using large datasets from the UK and the USA. The system outperformed radiologists in daily predictions, according to the researchers. They confirmed these observations with an independently conducted reader study. The system could generalize across different screening populations and settings without additional training data.

The AI system might reduce the workload involved in the double-reading process used in the UK while preserving the standard of care. The system could also provide automated, immediate feedback in the screening setting. This technology can sort cases at the risk level, making it possible to screen efficiently even with a limited workforce.

Overall, the AI was better than radiologists at identifying breast cancer. These results held across two large datasets that represent different screening populations and practices. However, the optimal use of the AI system within clinical workflows remains to be determined.

Cover image taken from the journal article. 

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.